← All trials
NCT05077501
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 29, 2021
- Primary completion
- Mar 8, 2022
- Completion date
- Mar 22, 2022
- First posted
- Oct 14, 2021
- Last posted
- Oct 22, 2021
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AlzeCure PharmaLead sponsor
- AlzeCure PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.